Ribosomal protein L22 pseudogene 22 (RPL22P22)

Ribosomal protein L22 pseudogene 22 (RPL22P22) is a non-functional copy of the ribosomal protein L22 gene, classified as a processed pseudogene. Pseudogenes are DNA segments similar to known genes but lacking the ability to encode functional products due to mutations, truncations, or absence of essential regulatory elements. The true protein-coding gene, ribosomal protein L22 (RPL22), encodes a structural protein of the large 60S ribosomal subunit used in protein synthesis, but pseudogene family members such as RPL22P22 do not produce functional protein. RPL22P22, as a pseudogene, is not considered a therapeutic target, nor is it known to have any established biological function, disease role, or drug interactions. Its presence in the genome is the result of gene duplication and retrotransposition events typical of ribosomal protein genes, which often generate multiple dispersed pseudogenes. Many ribosomal protein genes have multiple processed pseudogenes in the human genome. Ribosomal protein L22 itself (RPL22) is studied as a protein-coding gene with roles in translation and disease, but pseudogenes like RPL22P22 are not protein-coding and have no known function or clinical relevance. Older literature sometimes confused pseudogenes for the actual functional gene, especially in early chromosomal mapping studies relevant to leukemia, but subsequent research clarified their non-coding, non-functional status. No drugs, biomarkers, or therapeutic agents are known to interact with RPL22P22. RPL22P22 (ribosomal protein L22 pseudogene 22) is a non-coding pseudogene, not a therapeutic target, and contains no established function, disease association, or pharmacological role. The entry is considered "incorrect" for standard drug-target lists because it represents a pseudogene, not a receptor, enzyme, or relevant molecular target.

Other names

RPL22 pseudogene 22RPL22P22ribosomal protein L22 pseudogene 22processed pseudogene of RPL22